2025年3月27日下午，美国威斯康星大学麦迪逊分校胡全银副教授应邀做客转化医学STAR论坛，作主题为“Engineering cells for cancer immunotherapy”的精彩报告。本次论坛由上海交通大学医学院附属瑞金医院倪大龙教授主持，报告吸引了来自上海交通大学医学院、药学院、转化医学研究院、材料科学与工程学院等多个单位的师生到场聆听。
胡全银教授团队瞄准了工程化细胞这一研究方向，并聚焦于内源性细胞的药物递送系统。他指出，血小板作为一种内源性细胞，输注体内后不会受到人体免疫系统攻击，同时血小板在体内具有再生性，有利于临床大规模生产应用。在报告中，胡全银教授介绍了其团队通过启动肿瘤局部凝血信号级联，利用血小板固有的凝血响应性增加aPD-1抗体修饰的血小板（P-aPD-1）在肿瘤部位的蓄积，凝血级联反应进一步触发血小板活化以分泌血小板衍生微粒（PMP），并在肿瘤部位释放aPD-1抗体以重振T细胞，从而增强免疫反应。胡教授还介绍了基于血小板的靶向蛋白降解方法，将血小板作为天然载体，选择性地积累在出血区域，并通过激活释放HSP90，实现对目标蛋白质的降解，同时促进巨噬细胞向M2型极化。针对肿瘤免疫治疗，胡全银教授团队构建了可注射的基因纳米载体-水凝胶超结构递药系统，通过“原位改造”巨噬细胞生成 CAR-M，使其能特异性识别、吞噬脑胶质瘤干细胞，发挥抗原递呈作用，进而激活适应性免疫系统，并成功应用于恶性脑胶质瘤动物模型的术后免疫治疗。最后，胡教授对内源性细胞作为药物递送系统进行了总结和展望。
报告结束后，胡全银教授和与会师生就血小板识别肿瘤的具体机制、工程化血小板制备过程及其临床应用前景等相关问题进行了热烈讨论。此次交流深化了大家对内源性细胞作为药物递送系统相关研究进展的理解，师生们在交流中受益匪浅。
主讲人介绍
Dr. Quanyin Hu is a Vilas Associate Professor at the School of Pharmacy, University of Wisconsin-Madison (UW-Madison). He received his Ph.D. degree in Biomedical Engineering at the University of North Carolina at Chapel Hill (UNC-CH) and North Carolina State University from 2014-2018. Before he joined UW-Madison, he was a postdoc associate at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) from 2018-2020. Dr. Hu is currently serving as the Associate Editor for the Journal of Nanobiotechnology, Young Star Editor for Nano Research, and Guest Editor for Bioactive Materials. He has published more than 90 research papers, including Nature Biotechnology, Nature Nanotechnology, Nature Biomedical Engineering, Nature Review Bioengineering, Science Translational Medicine, Science Advances, and Nature Communications, with over 16,000 citations. Dr. Hu is recognized as NCI R01 awardee, NIBIB R01 Awardee, NIBIB Trailblazer, American Cancer Society (ACS) Research Scholar, V Foundation Scholar, the MIT Innovators under 35 (TR35) China, the 2023 BMES-CMBE Rising Star Junior Faculty, 2023 Journal of Nanobiotechnology Rising Star, 2022 iCANX Young Scientist, UW Madison Early Career Innovator, Clarivate Highly Cited Researcher (2022-2024), Young Investigator from many societies and Foundations, Emerging Investigator from many journals.
